2. Academic Validation
  3. Reverse fosmidomycin derivatives against the antimalarial drug target IspC (Dxr)

Reverse fosmidomycin derivatives against the antimalarial drug target IspC (Dxr)

  • J Med Chem. 2011 Oct 13;54(19):6796-802. doi: 10.1021/jm200694q.
Christoph T Behrendt 1,  Andrea Kunfermann,  Victoria Illarionova,  An Matheeussen,  Miriam K Pein,  Tobias Gräwert,  Johannes Kaiser,  Adelbert Bacher,  Wolfgang Eisenreich,  Boris Illarionov,  Markus Fischer,  Louis Maes,  Michael Groll,  Thomas Kurz
Affiliations

Affiliation

  • 1 Institut für Pharmazeutische und Medizinische Chemie, Heinrich Heine Universität, Universitätsstrasse 1, 40225 Düsseldorf, Germany.
PMID: 21866890 DOI: 10.1021/jm200694q
Abstract

Reverse hydroxamate-based inhibitors of IspC, a key enzyme of the non-mevalonate pathway of isoprenoid biosynthesis and a validated antimalarial target, were synthesized and biologically evaluated. The binding mode of one derivative in complex with EcIspC and a divalent metal ion was clarified by X-ray analysis. Pilot experiments have demonstrated in vivo potential.

Figures
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z